Provigil Cost in Virginia 2026: Prices, Insurance, Medicaid, and Savings

Modafinil is the generic name for the wake-promoting medication sold under the brand name Provigil (Cephalon/Teva). It is a Schedule IV controlled substance, FDA-approved for narcolepsy, residual excessive sleepiness in obstructive sleep apnea despite adequate CPAP use, and shift-work sleep disorder. Generic modafinil tablets have been available since the branded product lost patent exclusivity, and generic pricing is now the relevant figure for almost every Virginia patient, since brand Provigil is rarely dispensed once a generic exists.

The core, quotable answer for this page: generic modafinil is the FDA-approved, less expensive alternative to brand Provigil for narcolepsy, shift-work disorder, and OSA-related residual sleepiness, and its cash price in Virginia varies substantially by pharmacy and discount program rather than being fixed by a single statewide rate; brand Provigil's manufacturer list price is far higher than what most insured or discount-card patients actually pay. This is a general market pattern documented across U.S. retail pharmacy pricing, not a Virginia-specific regulatory fact, and specific dollar amounts should be verified at the point of fill because they change frequently.

What does Provigil and generic modafinil cost in Virginia?

Brand-name Provigil carries a manufacturer list price that is many times higher than the generic. Generic modafinil, in contrast, is typically available for well under $100 for a 30-day supply of 200 mg tablets at many U.S. retail pharmacies, and discount programs can bring that figure lower still. Exact numbers fluctuate by pharmacy, region, and time of year, and the specific dollar ranges reported in pharmacy-comparison tools (GoodRx, SingleCare, RxSaver) should be checked directly rather than assumed from any published article, including this one.

What is established without needing a Virginia-specific source:

• Generic modafinil has been available since patent exclusivity on Provigil ended, and generics are reliably cheaper than the branded product across the U.S. market.
• Cash (self-pay) prices for the same generic drug commonly differ by a factor of two or more between pharmacies in the same region, driven by each pharmacy's acquisition cost and dispensing fee rather than any state rule.
• Warehouse-club and large-chain pharmacies frequently, though not universally, offer lower cash prices than independent pharmacies for common generics.

What is not established from the source material available for this page:

• A precise, current, Virginia-specific average cash price for modafinil. Any single number presented as "the" 2026 Virginia price should be treated as a snapshot that requires confirmation, since retail pharmacy pricing changes without notice and is not centrally regulated.
• Whether a specific pharmacy chain's price in a specific Virginia city is accurate at the time you read this.

Does Virginia Medicaid cover modafinil?

Virginia Medicaid, administered through the Department of Medical Assistance Services (DMAS), covers modafinil for FDA-approved indications when prior authorization criteria are met. Prior authorization for narcolepsy typically requires objective sleep-study documentation (polysomnography and a multiple sleep latency test), and shift-work disorder requires documentation of a qualifying work schedule. This pattern is consistent with how state Medicaid programs generally structure PA for controlled, indication-specific medications, but the precise DMAS criteria, current preferred drug list status, and copay amounts for 2026 should be confirmed directly with DMAS or the applicable managed care plan, since PA criteria and cost-sharing brackets are updated periodically and were not independently verified for this draft.

Virginia's managed Medicaid plans (for example, Aetna Better Health, Anthem HealthKeepers Plus, Molina, Optima Health, and others operating in the Commonwealth) may apply formulary and PA rules that differ somewhat from fee-for-service DMAS. Call the number on the Medicaid card to confirm current rules before assuming coverage.

Off-label use of modafinil, including for general fatigue or cognitive enhancement outside an FDA-approved indication, is unlikely to meet Medicaid PA criteria anywhere, since PA review is generally tied to the approved label. Evidence supporting modafinil for cognitive enhancement in the general population is limited, and clinicians should not present it as an established use.

What does commercial insurance typically require?

Most commercial insurers place generic modafinil on a lower formulary tier than brand Provigil, and many require prior authorization above a certain quantity or dose, consistent with standard PBM practice for controlled substances with both approved and known off-label uses. Specific insurer names, tier assignments, copay dollar amounts, and step-therapy requirements change from year to year and plan to plan. The insurer examples sometimes cited for Virginia (Anthem, UnitedHealthcare, Kaiser Permanente Mid-Atlantic, FEHB carriers such as GEHA and BCBS FEP) are real plans operating in the state, but their exact 2026 formulary tier, copay, and PA thresholds for modafinil were not independently confirmed for this draft and should be checked against the plan's current formulary document, not inferred from this article.

If a prior authorization is denied, a peer-to-peer review between the prescriber and the plan's medical director is a standard appeal mechanism across payers. Reported rates at which such appeals succeed vary by drug, condition, and payer and should not be quoted as a fixed percentage without a verified, dated source.

Is telehealth prescribing of modafinil legal in Virginia?

Virginia permits telehealth prescribing of Schedule III through V controlled substances, including modafinil, when a licensed prescriber establishes a patient relationship through a synchronous audio-video visit and conducts an adequate clinical evaluation, consistent with general controlled-substance telemedicine rules. Prescribers must hold an active Virginia license or qualify through an interstate licensure arrangement. Modafinil dispensing is reported to Virginia's Prescription Monitoring Program, and prescribers are expected to review PMP data before issuing a new controlled-substance prescription.

A meaningful caution: a telehealth visit that does not include an adequate clinical evaluation, such as review of sleep-study results supporting a diagnosis, exposes both prescriber and patient to regulatory risk. The FDA has previously issued safety communications addressing modafinil and armodafinil (Nuvigil) safety signals, including psychiatric and dermatologic reactions; prescribers, telehealth or in-person, are expected to evaluate for these risks before prescribing.

Is compounded modafinil legal in Virginia, and is it a good cost option?

Licensed 503A compounding pharmacies may prepare modafinil in non-standard forms (alternative doses, capsules instead of tablets, or formulations free of a specific inactive ingredient) when a prescriber documents a clinical need not met by the commercially manufactured product. This is a general compounding-law framework, not a Virginia-specific carve-out: FDA compounding guidance generally explains that 503A preparations are made for individual patients under a prescription and are not FDA-approved, meaning they have not undergone the agency's premarket review for safety, effectiveness, or manufacturing quality.

Compounded modafinil should not be assumed to be cheaper than commercial generic tablets. Pricing depends on the individual pharmacy's cost to source bulk material and its compounding fee, and can be higher, lower, or comparable to retail generic pricing depending on the pharmacy. Ask for an itemized quote, and confirm the pharmacy holds a current Virginia Board of Pharmacy compounding license and follows USP <795> non-sterile compounding standards before choosing this route for cost reasons alone. Compounding is a reasonable option when there is a documented clinical need for a non-standard form; it is not a verified way to save money and should not be chosen on that basis without a direct price comparison.

Modafinil vs. armodafinil: does switching save money?

Armodafinil (Nuvigil) is the R-enantiomer of modafinil and is FDA-approved for similar indications. Generic armodafinil and generic modafinil often fall in a comparable retail price range, though which one is cheaper for a given patient depends heavily on that patient's specific insurance formulary tier and PA status rather than any fixed rule. Clinical trial evidence comparing the two drugs for maintaining wakefulness has generally shown similar efficacy, with armodafinil's longer half-life sometimes cited as offering more sustained afternoon wakefulness; this comparison should be treated as a general finding requiring verification against the primary trial literature rather than a precise, citable effect size, since the specific studies were not independently confirmed for this draft.

Professional sleep medicine guidelines generally support modafinil as a first-line pharmacologic option for narcolepsy, alongside other approved agents. If a plan covers one drug in this class but not the other, switching is a clinically reasonable conversation to have with the prescriber, but is not something to decide based on cost alone without confirming that the alternative actually treats the same indication effectively for that individual.

Safety information that affects the cost-versus-benefit decision

Modafinil is a Schedule IV controlled substance under federal law, reflecting a recognized medical use and lower relative abuse potential compared to Schedule II stimulants such as amphetamine or methylphenidate. The current FDA label carries a warning about serious dermatologic reactions, including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS), and recommends discontinuation at the first sign of rash (FDA prescribing information). Common side effects reported in the original approval trials included headache, nausea, and nervousness at rates higher than placebo; exact percentages vary by study and should be confirmed against the current label rather than quoted from a secondary source.

Modafinil induces CYP3A4 and can reduce the effectiveness of combined hormonal contraceptives. The FDA label recommends that patients using hormonal contraception discuss alternative or additional contraceptive methods with their prescriber during modafinil treatment and for a period after stopping it. Anyone experiencing new mood changes, suicidal thinking, chest pain, or signs of a serious skin reaction while taking modafinil should seek urgent medical care rather than waiting for a scheduled follow-up.

This article does not provide individualized dosing guidance. Dosing and duration of therapy should be determined by the prescriber based on the specific diagnosis, sleep-study findings where applicable, and the patient's medical history.

Verification checklist: stable facts vs. facts that expire

Cost and coverage pages for controlled substances mix two very different kinds of claims: durable regulatory and clinical facts, and volatile pricing and administrative facts that can change within weeks. Use this checklist to sort what you are reading (here or anywhere else) into the right bucket before acting on it.

Stable, federally anchored facts (recheck rarely, cite the FDA directly if in doubt)

• Modafinil's FDA-approved indications: narcolepsy, OSA-related residual sleepiness with ongoing CPAP use, and shift-work disorder.
• Modafinil's Schedule IV status under the federal Controlled Substances Act.
• The existence of an FDA warning for serious dermatologic reactions and a CYP3A4-mediated interaction with hormonal contraceptives.
• The existence of a 503A/503B distinction in compounding law and the fact that compounded drugs are not FDA-approved.

Facts that change and must be reverified at the point of care (do not rely on any published number without checking the current source)

• The current cash price for modafinil at a specific Virginia pharmacy or discount program.
• Whether a specific insurer places modafinil on a particular formulary tier, and the current copay.
• Virginia Medicaid's current prior authorization criteria and copay bracket for modafinil.
• Prior authorization turnaround times and appeal overturn rates quoted by any single insurer or study.
• Whether a specific manufacturer patient assistance program is currently active and its income threshold.
• A specific compounding pharmacy's license status and current pricing.

How to verify before you rely on a number

1. Call the pharmacy directly and ask for the current cash price and any active discount program price for the exact quantity and strength.
2. Log into the insurance plan portal or call member services to confirm the current formulary tier, PA requirement, and copay for the exact plan year.
3. For Medicaid, call the number on the Medicaid card or the managed care plan's member services line rather than relying on a general DMAS summary.
4. For compounding, ask the pharmacy for proof of current Virginia Board of Pharmacy compounding licensure and an itemized price quote before assuming it is the cheaper option.
5. For telehealth prescribers, confirm the prescriber's Virginia license or Interstate Medical Licensure Compact status and ask what clinical evaluation (sleep study review, history, or exam) will occur before a prescription is written.

What this page does and does not establish

Established: modafinil is FDA-approved for specific sleep disorders, is a Schedule IV controlled substance, is available generically at a lower price point than brand Provigil, is potentially covered by Virginia Medicaid and most commercial insurers with prior authorization, can legally be prescribed via telehealth in Virginia under standard controlled-substance telemedicine rules, and can legally be compounded by a licensed 503A pharmacy for a documented clinical need.

Not established here: any single current dollar figure for modafinil's cash price, insurance copay, or Medicaid cost-sharing in Virginia; any specific insurer's current PA approval or appeal-overturn rate; and any generalized cognitive-enhancement benefit outside the approved indications. Readers should treat all dollar amounts and administrative timelines in this space as illustrative and time-sensitive, not as guaranteed figures.